Last updated: 2026-11-14 09:52:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ensysce Biosciences, Inc. (ENSC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.42, with a market capitalization of $7.53M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.23 to $2.17. This page covers its latest market performance, valuation, price trends and company information.
$7.53M | |
$0.45 | |
$0.45 | |
$0.37 | |
$0.39 | |
411.95K | |
588.74K | |
-- | |
$2.17 | |
$0.23 | |
-- | |
-- |
Ensysce Biosciences, Inc. (ENSC) last closed at $0.42 as of 2026-11-14 00:48:00, up 6.95% ($0.03) from the previous close of $0.39.
During the latest regular trading session, ENSC traded between $0.37 and $0.45, with a volume of 411.95K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Ensysce Biosciences, Inc. (ENSC) moved from $0.36 to $0.42, representing a gain of 15.24% ($0.05).
The stock traded between $0.30 and $0.45 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 316.61 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 9.6%
ENSC is currently trading at $0.42, placing it 9.6% of the way from its 52-week low of $0.23 to its 52-week high of $2.17. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Ensysce Biosciences, Inc. and ENSC stock.
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 89.92 percent increase over losses of $(1.29) per share
Analysts initiated coverage on KE, MBX, ENSC, DORM and AGLT, issuing mostly Buy/positive ratings with new price targets.
UBS analyst Ashwani Verma initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Buy rating and announces Price Target of $2.
Eligible investors can buy real shares of Ensysce Biosciences, Inc. (ENSC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ENSC, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ENSC shares and USD.
ENSC Shares to USD
1.00 ENSC shares = 0.416 USD
Calculations are estimates based on the latest available price and are for reference only.
